<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34484759</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2050-0904</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical case reports</Title><ISOAbbreviation>Clin Case Rep</ISOAbbreviation></Journal><ArticleTitle>Hypertension as a manifestation of COVID-19 pneumonia.</ArticleTitle><Pagination><StartPage>e04720</StartPage><MedlinePgn>e04720</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e04720</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccr3.4720</ELocationID><Abstract><AbstractText>Several factors such as hypertension, bile duct disease, and age can affect the duration of COVID, which can lead to long COVID. Any course of coronavirus infection could have a diverse nature of clinical forms and should have a personalized approach.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Clinical Case Reports published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bekbossynova</LastName><ForeName>Makhabbat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3437-0512</Identifier><AffiliationInfo><Affiliation>Non-commercial joint-stock company National Research Center for Cardiac Surgery Nur-Sultan Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ainur</LastName><ForeName>Tauekelova</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Non-commercial joint-stock company National Research Center for Cardiac Surgery Nur-Sultan Kazakhstan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Case Rep</MedlineTA><NlmUniqueID>101620385</NlmUniqueID><ISSNLinking>2050-0904</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19 pneumonia</Keyword><Keyword MajorTopicYN="N">arterial hypertension ACE2 receptors</Keyword><Keyword MajorTopicYN="N">case study</Keyword><Keyword MajorTopicYN="N">coronavirus infection</Keyword><Keyword MajorTopicYN="N">initial manifestation</Keyword><Keyword MajorTopicYN="N">long COVID syndrome</Keyword><Keyword MajorTopicYN="N">postviral inflammatory complications</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34484759</ArticleId><ArticleId IdType="pmc">PMC8405430</ArticleId><ArticleId IdType="doi">10.1002/ccr3.4720</ArticleId><ArticleId IdType="pii">CCR34720</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade&#x2010;long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127&#x2010;e220. doi:10.1128/JVI.00127-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00127-20</ArticleId><ArticleId IdType="pmc">PMC7081895</ArticleId><ArticleId IdType="pubmed">31996437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin&#x2010;converting enzyme 2 (ACE2) as a SARS&#x2010;CoV&#x2010;2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586&#x2010;590. 10.1007/s00134-020-05985-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05985-9</ArticleId><ArticleId IdType="pmc">PMC7079879</ArticleId><ArticleId IdType="pubmed">32125455</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID&#x2010;19 infection? Lancet Respir Med. 2020;8(4):e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118626</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Norrie JD. Remdesivir for COVID&#x2010;19: challenges of underpowered studies. The Lancet. 2020;395(10236):1525&#x2013;1527. 10.1016/s0140-6736(20)31023-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31023-0</ArticleId><ArticleId IdType="pmc">PMC7190306</ArticleId><ArticleId IdType="pubmed">32423580</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreary EK, Angus DC. Efficacy of Remdesivir in COVID&#x2010;19. JAMA. 2020;324(11):1041. 10.1001/jama.2020.16337</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16337</ArticleId><ArticleId IdType="pubmed">32821934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine&#x2010;Weber H, Kr&#xfc;ger N, et al. The novel coronavirus 2019 (2019&#x2010;nCoV) uses the SARS&#x2010;1 coronavirus receptor2 ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. in press. 2020. doi:10.1101/2020.01.31.929042</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.01.31.929042</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019&#x2010;nCoV infection. bioRxiv. 2020. doi:10.1101/2020.02.03.931766</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.03.931766</ArticleId></ArticleIdList></Reference><Reference><Citation>Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019;16(5):269&#x2010;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563606</ArticleId><ArticleId IdType="pubmed">30850822</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>